GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OncoCyte Corp (LTS:0KCC) » Definitions » Cyclically Adjusted PB Ratio

OncoCyte (LTS:0KCC) Cyclically Adjusted PB Ratio : 0.25 (As of Jun. 11, 2024)


View and export this data going back to 2018. Start your Free Trial

What is OncoCyte Cyclically Adjusted PB Ratio?

As of today (2024-06-11), OncoCyte's current share price is $2.6314. OncoCyte's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $10.68. OncoCyte's Cyclically Adjusted PB Ratio for today is 0.25.

The historical rank and industry rank for OncoCyte's Cyclically Adjusted PB Ratio or its related term are showing as below:

LTS:0KCC' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.24   Med: 0.27   Max: 0.29
Current: 0.27

During the past years, OncoCyte's highest Cyclically Adjusted PB Ratio was 0.29. The lowest was 0.24. And the median was 0.27.

LTS:0KCC's Cyclically Adjusted PB Ratio is ranked better than
84.67% of 137 companies
in the Medical Diagnostics & Research industry
Industry Median: 2 vs LTS:0KCC: 0.27

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

OncoCyte's adjusted book value per share data for the three months ended in Mar. 2024 was $1.401. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $10.68 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


OncoCyte Cyclically Adjusted PB Ratio Historical Data

The historical data trend for OncoCyte's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Cyclically Adjusted PB Ratio Chart

OncoCyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

OncoCyte Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.29

Competitive Comparison of OncoCyte's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, OncoCyte's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoCyte's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, OncoCyte's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where OncoCyte's Cyclically Adjusted PB Ratio falls into.



OncoCyte Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

OncoCyte's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.6314/10.68
=0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoCyte's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, OncoCyte's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.401/131.7762*131.7762
=1.401

Current CPI (Mar. 2024) = 131.7762.

OncoCyte Quarterly Data

Book Value per Share CPI Adj_Book
201312 11.123 98.326 14.907
201409 0.000 100.428 0.000
201412 -3.305 99.070 -4.396
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 7.043 100.392 9.245
201512 8.205 99.792 10.835
201603 5.427 100.470 7.118
201606 3.513 101.688 4.552
201609 8.844 101.861 11.441
201612 6.864 101.863 8.880
201703 5.975 102.862 7.655
201706 3.820 103.349 4.871
201709 5.123 104.136 6.483
201712 2.800 104.011 3.547
201803 4.771 105.290 5.971
201806 3.474 106.317 4.306
201809 3.700 106.507 4.578
201812 1.684 105.998 2.094
201903 14.695 107.251 18.055
201906 12.893 108.070 15.721
201909 11.289 108.329 13.732
201912 10.814 108.420 13.144
202003 11.723 108.902 14.185
202006 11.780 108.767 14.272
202009 10.301 109.815 12.361
202012 9.689 109.897 11.618
202103 23.984 111.754 28.281
202106 22.735 114.631 26.135
202109 21.561 115.734 24.550
202112 14.142 117.630 15.843
202203 12.351 121.301 13.418
202206 14.037 125.017 14.796
202209 12.959 125.227 13.637
202212 5.781 125.222 6.084
202303 6.360 127.348 6.581
202306 5.291 128.729 5.416
202309 4.547 129.860 4.614
202312 2.478 129.419 2.523
202403 1.401 131.776 1.401

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


OncoCyte  (LTS:0KCC) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


OncoCyte Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of OncoCyte's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoCyte (LTS:0KCC) Business Description

Traded in Other Exchanges
Address
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States.

OncoCyte (LTS:0KCC) Headlines

No Headlines